Simplex Trading’s Altamira Therapeutics Ltd CYTO Stock Holding History

Simplex Trading’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9	Closed	-$6K	–	11707
2021 Q4	$6K	Buy	+9	New	+$6.03K	﹤0.01%	9464
2021 Q3	–	Sell	-62	Closed	-$6K	–	9935
2021 Q2	$6K	Buy	+62	New	+$85.1K	﹤0.01%	9423
2016 Q2	–	Hold	0	–	-$1K	–	6624
2016 Q1	–	Hold	0	–	–	–	5285

Other funds holding CYTO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SCA

Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

Simplex Trading's CYTO Position: Q4 2022 in Review

Simplex Trading sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2022, closing a stake of 19 shares — an estimated $2K sold.

Simplex Trading first reported a position in CYTO in Q1 2021 and held it in 5 quarters. The position peaked at $47K in Q2 2021. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2022.

Simplex Trading reported no remaining Altamira Therapeutics Ltd position as of Q4 2022 after selling out during the quarter.
Simplex Trading sold 19 Altamira Therapeutics Ltd shares in Q4 2022, an estimated $2K.
Simplex Trading first reported a position in Altamira Therapeutics Ltd in Q1 2021 and held it in 5 quarters.
Simplex Trading's Altamira Therapeutics Ltd position peaked at $47K in Q2 2021.
6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2022.

Based on Simplex Trading's 13F filing for Q4 2022, filed 2 Feb 2023.